How to Identify High-Risk Patients in Inflammatory Bowel Disease?

Chapter

Abstract

Patients with inflammatory bowel disease (IBD) developing a disabling or complicated course would beneficiate of an early aggressive treatment. Identifying these patients in the early time of the disease is mandatory to use this strategy. In this article, we reviewed predictive factors according to the time during the disease course and type of IBD.

The most important clinical predictors of disease course are age at disease onset, severity of the first flare, perianal location and smoking in Crohn’s disease, very young age and disease extent in ulcerative colitis. Biological parameters such as gene polymorphisms and serologic markers are not accurate enough to guide patient treatment yet. Despite many progress, we are still not able to predict the disease course in the long term at the patient level. Thus, prediction should be given with caution to a patient. In the future, genetic and serological markers combined with other biological and clinical markers could be associated in more powerful composite predicting tools.

Keywords

Crohn’s disease Ulcerative colitis Natural history Prognosis 

References

  1. 1.
    Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology. 2009;136:1182–97.PubMedCrossRefGoogle Scholar
  2. 2.
    Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology. 2006;130:650–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol. 2008;43:948–54.PubMedCrossRefGoogle Scholar
  4. 4.
    Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis. 2002;8:244–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Munkholm P, Langholz E, Davidsen M, et al. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol. 1995;30:699–706.PubMedCrossRefGoogle Scholar
  6. 6.
    Mekhjian HS, Switz DM, Melnyk CS, et al. Clinical features and natural history of Crohn’s disease. Gastroenterology. 1979;77:898–906.PubMedGoogle Scholar
  7. 7.
    Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn’s disease: implications for early treatment strategies. Am J Gastroenterol. 2003;98:2712–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Andersson P, Olaison G, Hallbook O, et al. Segmental resection or subtotal colectomy in Crohn’s colitis? Dis Colon Rectum. 2002;45:47–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Galandiuk S, Kimberling J, Al-Mishlab TG, et al. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg. 2005;241:796–801. discussion 801-2.PubMedCrossRefGoogle Scholar
  10. 10.
    Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn’s disease. Aliment Pharmacol Ther. 2007;25:861–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.PubMedGoogle Scholar
  12. 12.
    Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007;132:507–15.PubMedCrossRefGoogle Scholar
  13. 13.
    Dunckley P, Jewell D. Management of acute severe colitis. Best Pract Res Clin Gastroenterol. 2003;17:89–103.PubMedCrossRefGoogle Scholar
  14. 14.
    Winther KV, Jess T, Langholz E, et al. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology. 2003;125:1576–82.PubMedCrossRefGoogle Scholar
  15. 15.
    Shen B, Fazio VW, Remzi FH, et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am J Gastroenterol. 2005;100:93–101.PubMedCrossRefGoogle Scholar
  16. 16.
    Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35–40.PubMedCrossRefGoogle Scholar
  18. 18.
    Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895–902.PubMedCrossRefGoogle Scholar
  19. 19.
    Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut. 2008;57:331–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol. 2009;104:2080–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Tremaine WJ, Timmons LJ, Loftus Jr EV, et al. Age at onset of inflammatory bowel disease and the risk of surgery for non-neoplastic bowel disease. Aliment Pharmacol Ther. 2007;25:1435–41.PubMedCrossRefGoogle Scholar
  22. 22.
    Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009;104:371–83.PubMedCrossRefGoogle Scholar
  24. 24.
    Hofer B, Bottger T, Hernandez-Richter T, et al. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn’s disease. Hepatogastroenterology. 2001;48:152–5.PubMedGoogle Scholar
  25. 25.
    Scarpa M, Ruffolo C, Bertin E, et al. Surgical predictors of recurrence of Crohn’s disease after ileocolonic resection. Int J Colorectal Dis. 2007;22:1061–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Wolters FL, Russel MG, Sijbrandij J, et al. Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut. 2006;55:510–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Melton GB, Kiran RP, Fazio VW, et al. Do preoperative factors predict subsequent diagnosis of Crohn’s disease after ileal pouch-anal anastomosis for ulcerative or indeterminate colitis? Colorectal Dis. 2010;12:1026–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Cottone M, Kohn A, Daperno M, et al. Age is a risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–25.PubMedCrossRefGoogle Scholar
  30. 30.
    Henriksen M, Jahnsen J, Lygren I, et al. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008;57:1518–23.PubMedCrossRefGoogle Scholar
  31. 31.
    Langholz E, Munkholm P, Davidsen M, et al. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996;31:260–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn’s disease. Gut. 2006;55:1124–30.PubMedCrossRefGoogle Scholar
  33. 33.
    Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn’s disease. Br J Surg. 2000;87:1697–701.PubMedCrossRefGoogle Scholar
  34. 34.
    Baldassano RN, Han PD, Jeshion WC, et al. Pediatric Crohn’s disease: risk factors for postoperative recurrence. Am J Gastroenterol. 2001;96:2169–76.PubMedCrossRefGoogle Scholar
  35. 35.
    Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn’s disease. Gastroenterology. 1994;106:643–8.PubMedGoogle Scholar
  36. 36.
    Vermeire S, Van Assche G, Rutgeerts P. Perianal Crohn’s disease: classification and clinical evaluation. Dig Liver Dis. 2007;39:959–62.PubMedCrossRefGoogle Scholar
  37. 37.
    Schwartz DA, Loftus Jr EV, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology. 2002;122:875–80.PubMedCrossRefGoogle Scholar
  38. 38.
    Veloso FT, Ferreira JT, Barros L, et al. Clinical outcome of Crohn’s disease: analysis according to the vienna classification and clinical activity. Inflamm Bowel Dis. 2001;7:306–13.PubMedCrossRefGoogle Scholar
  39. 39.
    Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg. 2000;231:38–45.PubMedCrossRefGoogle Scholar
  40. 40.
    Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009;44:431–40.PubMedCrossRefGoogle Scholar
  41. 41.
    Langholz E, Munkholm P, Davidsen M, et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992;103:1444–51.PubMedGoogle Scholar
  42. 42.
    Ekbom A, Helmick CG, Zack M, et al. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology. 1992;103:954–60.PubMedGoogle Scholar
  43. 43.
    Achkar JP, Al-Haddad M, Lashner B, et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol. 2005;3:60–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Schmidt CM, Lazenby AJ, Hendrickson RJ, et al. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg. 1998;227:654–62. discussion 663-5.PubMedCrossRefGoogle Scholar
  45. 45.
    Wolters FL, Joling C, Russel MG, et al. Treatment inferred disease severity in Crohn’s disease: evidence for a European gradient of disease course. Scand J Gastroenterol. 2007;42:333–44.PubMedCrossRefGoogle Scholar
  46. 46.
    Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohn’s disease patients. Clin Gastroenterol Hepatol. 2009;7:972–980.e2.PubMedCrossRefGoogle Scholar
  47. 47.
    Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn’s disease: evidence for two clinical forms. Gut. 1988;29:588–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Aeberhard P, Berchtold W, Riedtmann HJ, et al. Surgical recurrence of perforating and nonperforating Crohn’s disease. A study of 101 surgically treated patients. Dis Colon Rectum. 1996;39:80–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Avidan B, Sakhnini E, Lahat A, et al. Risk factors regarding the need for a second operation in patients with Crohn’s disease. Digestion. 2005;72:248–53.PubMedCrossRefGoogle Scholar
  50. 50.
    Hamon JF, Carbonnel F, Beaugerie L, et al. Comparison of long-term course of perforating and non-perforating Crohn disease. Gastroenterol Clin Biol. 1998;22:601–6.PubMedGoogle Scholar
  51. 51.
    Yamamoto T, Allan RN, Keighley MR. Perforating ileocecal Crohn’s disease does not carry a high risk of recurrence but usually re-presents as perforating disease. Dis Colon Rectum. 1999;42:519–24.PubMedCrossRefGoogle Scholar
  52. 52.
    Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2,402 patients. Medicine (Baltimore). 2008;87:281–93.CrossRefGoogle Scholar
  53. 53.
    Bardazzi G, Mannoni A, d’Albasio G, et al. Spondyloarthritis in patients with ulcerative colitis. Ital J Gastroenterol Hepatol. 1997;29:520–4.PubMedGoogle Scholar
  54. 54.
    Fleshner P, Ippoliti A, Dubinsky M, et al. A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis. Clin Gastroenterol Hepatol. 2007;5:952–8. quiz 887.PubMedCrossRefGoogle Scholar
  55. 55.
    Shen B, Fazio VW, Remzi FH, et al. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:81–9. quiz 2-3.PubMedCrossRefGoogle Scholar
  56. 56.
    Hoda KM, Collins JF, Knigge KL, et al. Predictors of pouchitis after ileal pouch-anal anastomosis: a retrospective review. Dis Colon Rectum. 2008;51:554–60.PubMedCrossRefGoogle Scholar
  57. 57.
    Kuisma J, Jarvinen H, Kahri A, et al. Factors associated with disease activity of pouchitis after surgery for ulcerative colitis. Scand J Gastroenterol. 2004;39:544–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Hata K, Watanabe T, Shinozaki M, et al. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand J Gastroenterol. 2003;38:1055–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Loftus Jr EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Sokol H, Cosnes J, Chazouilleres O, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3497–503.PubMedCrossRefGoogle Scholar
  61. 61.
    Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long-term course of Crohn’s disease. Gastroenterology. 1996;110:424–31.PubMedCrossRefGoogle Scholar
  62. 62.
    Yamamoto T. Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol. 2005;11:3971–9.PubMedGoogle Scholar
  63. 63.
    Ryan WR, Allan RN, Yamamoto T, et al. Crohn’s disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg. 2004;187:219–25.PubMedCrossRefGoogle Scholar
  64. 64.
    Unkart JT, Anderson L, Li E, et al. Risk factors for surgical recurrence after ileocolic resection of Crohn’s disease. Dis Colon Rectum. 2008;51:1211–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Roth LS, Chande N, Ponich T, et al. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol. 2010;16:232–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Boyko EJ, Perera DR, Koepsell TD, et al. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol. 1988;23:1147–52.PubMedCrossRefGoogle Scholar
  67. 67.
    Beaugerie L, Massot N, Carbonnel F, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol. 2001;96:2113–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Szamosi T, Banai J, Lakatos L, et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn’s disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010;22:872–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol. 2004;18:481–96.PubMedCrossRefGoogle Scholar
  70. 70.
    Shen B, Fazio VW, Remzi FH, et al. Risk factors for clinical phenotypes of Crohn’s disease of the ileal pouch. Am J Gastroenterol. 2006;101:2760–8.PubMedCrossRefGoogle Scholar
  71. 71.
    Merrett MN, Mortensen N, Kettlewell M, et al. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut. 1996;38:362–4.PubMedCrossRefGoogle Scholar
  72. 72.
    Joelsson M, Benoni C, Oresland T. Does smoking influence the risk of pouchitis following ileal pouch anal anastomosis for ulcerative colitis? Scand J Gastroenterol. 2006;41:929–33.PubMedCrossRefGoogle Scholar
  73. 73.
    Cosnes J, Seksik P, Nion-Larmurier I, et al. Prior appendectomy and the phenotype and course of Crohn’s disease. World J Gastroenterol. 2006;12:1235–42.PubMedGoogle Scholar
  74. 74.
    Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of appendicectomy on the course of ulcerative colitis. Gut. 2002;51:803–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Radford-Smith GL, Edwards JE, Purdie DM, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn’s disease. Gut. 2002;51:808–13.PubMedCrossRefGoogle Scholar
  76. 76.
    Carbonnel F, Macaigne G, Beaugerie L, et al. Crohn’s disease severity in familial and sporadic cases. Gut. 1999;44:91–5.PubMedCrossRefGoogle Scholar
  77. 77.
    Henriksen M, Jahnsen J, Lygren I, et al. Are there any differences in phenotype or disease course between familial and sporadic cases of inflammatory bowel disease? Results of a population-based follow-up study. Am J Gastroenterol. 2007;102:1955–63.PubMedCrossRefGoogle Scholar
  78. 78.
    Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–62.PubMedCrossRefGoogle Scholar
  79. 79.
    Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn’s disease. Gastroenterology. 2002;123:679–88.PubMedCrossRefGoogle Scholar
  80. 80.
    Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn’s disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242:693–700.PubMedCrossRefGoogle Scholar
  81. 81.
    Potocnik U, Ferkolj I, Glavac D, et al. Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn disease and ulcerative colitis. Genes Immun. 2004;5:530–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003;178:339–46.PubMedCrossRefGoogle Scholar
  83. 83.
    Cucchiara S, Latiano A, Palmieri O, et al. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:171–9.PubMedCrossRefGoogle Scholar
  84. 84.
    Daniel F, Loriot MA, Seksik P, et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis. 2007;13:19–23.PubMedCrossRefGoogle Scholar
  85. 85.
    Hlavaty T, Pierik M, Henckaerts L, et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn’s disease. Aliment Pharmacol Ther. 2005;22:613–26.PubMedCrossRefGoogle Scholar
  86. 86.
    Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822–9.PubMedCrossRefGoogle Scholar
  87. 87.
    Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788–91.PubMedCrossRefGoogle Scholar
  88. 88.
    Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123:689–99.PubMedCrossRefGoogle Scholar
  89. 89.
    Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005;128:2020–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487–96.PubMedCrossRefGoogle Scholar
  91. 91.
    Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376–84.PubMedCrossRefGoogle Scholar
  92. 92.
    Amre DK, Lu SE, Costea F, et al. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn’s disease patients. Am J Gastroenterol. 2006;101:645–52.PubMedCrossRefGoogle Scholar
  93. 93.
    Dubinsky M. What is the role of serological markers in IBD? Pediatric and adult data. Dig Dis. 2009;27:259–68.PubMedCrossRefGoogle Scholar
  94. 94.
    Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology. 1996;110:1810–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Fleshner PR, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut. 2001;49:671–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Melmed GY, Fleshner PR, Bardakcioglu O, et al. Family history and serology predict Crohn’s disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum. 2008;51:100–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120:1093–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441–50 e1. quiz 716.PubMedCrossRefGoogle Scholar
  99. 99.
    Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135:1106–13.PubMedCrossRefGoogle Scholar
  100. 100.
    Wright JP. Factors influencing first relapse in patients with Crohn’s disease. J Clin Gastroenterol. 1992;15:12–6.PubMedCrossRefGoogle Scholar
  101. 101.
    Tan WC, Allan RN. Diffuse jejunoileitis of Crohn’s disease. Gut. 1993;34:1374–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Keh C, Shatari T, Yamamoto T, et al. Jejunal Crohn’s disease is associated with a higher postoperative recurrence rate than ileocaecal Crohn’s disease. Colorectal Dis. 2005;7:366–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360–7.PubMedCrossRefGoogle Scholar
  104. 104.
    Travis SP, Farrant JM, Ricketts C, et al. Predicting outcome in severe ulcerative colitis. Gut. 1996;38:905–10.PubMedCrossRefGoogle Scholar
  105. 105.
    Cacheux W, Seksik P, Lemann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008;103:637–42.PubMedCrossRefGoogle Scholar
  106. 106.
    Carbonnel F, Lavergne A, Lemann M, et al. Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci. 1994;39:1550–7.PubMedCrossRefGoogle Scholar
  107. 107.
    Radford-Smith GL. What is the importance of appendectomy in the natural history of IBD? Inflamm Bowel Dis. 2008;14 Suppl 2:S72–4.PubMedCrossRefGoogle Scholar
  108. 108.
    Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn’s disease. Gastroenterology. 1990;98:1123–8.PubMedGoogle Scholar
  109. 109.
    Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. Int J Colorectal Dis. 2008;23:1213–21.PubMedCrossRefGoogle Scholar
  110. 110.
    Yamamoto T, Allan RN, Keighley MR. Smoking is a predictive factor for outcome after colectomy and ileorectal anastomosis in patients with Crohn’s colitis. Br J Surg. 1999;86:1069–70.PubMedCrossRefGoogle Scholar
  111. 111.
    Hamilton SR. Pathologic features of Crohn’s disease associated with recrudescence after resection. Pathol Annu. 1983;18(Pt 1):191–203.PubMedGoogle Scholar
  112. 112.
    Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn’s disease. Gastroenterology. 1998;115:259–67.PubMedCrossRefGoogle Scholar
  113. 113.
    McDonald PJ, Fazio VW, Farmer RG, et al. Perforating and nonperforating Crohn’s disease. An unpredictable guide to recurrence after surgery. Dis Colon Rectum. 1989;32:117–20.PubMedCrossRefGoogle Scholar
  114. 114.
    Platell C, Mackay J, Woods R. A multivariate analysis of risk factors associated with recurrence following surgery for Crohn’s disease. Colorectal Dis. 2001;3:100–6.PubMedCrossRefGoogle Scholar
  115. 115.
    Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut. 1996;38:234–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Abdelrazeq AS, Kandiyil N, Botterill ID, et al. Predictors for acute and chronic pouchitis following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2008;10:805–13.PubMedCrossRefGoogle Scholar
  117. 117.
    Shen B, Remzi FH, Brzezinski A, et al. Risk factors for pouch failure in patients with different phenotypes of Crohn’s disease of the pouch. Inflamm Bowel Dis. 2008;14:942–8.PubMedCrossRefGoogle Scholar
  118. 118.
    Shen B, Remzi FH, Hammel JP, et al. Family history of Crohn’s disease is associated with an increased risk for Crohn’s disease of the pouch. Inflamm Bowel Dis. 2009;15:163–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Gastroenterology and NutritionSaint-AntoineParisFrance

Personalised recommendations